Assessing the Safety and Tolerability of CSL730 in Healthy Caucasian and Japanese Adults
Stopped The Sponsor decided to terminate this study in favor of development of subcutaneous administration.
Conditions
Interventions
- BIOLOGICAL: CSL730
- OTHER: Placebo
Sponsor
CSL Behring